Table 1.
Surface antigen | ALL subtype | Expression (%) | MoAb |
---|---|---|---|
CD20 | Mature B-cell precursor |
86-100 30-40 |
Rituximab, ofatumumab, obinituzumab |
CD19 | Mature B-cell precursor |
95-<100 95-<100 |
Blinatumomab |
CD22 | Mature B-cell precursor |
∼100 93-98 |
Inotuzumab ozogamicin, epratuzumab, moxetumomab pasudotox |
Adapted from Jabbour et al.2